Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
Chan Wu,1,* Yang Zhang,1,2,* Daoqiu Yang,3,* Jinfeng Zhang,4 Juanjuan Ma,1 Dan Cheng,1 Jianming Chen,1,5 Li Deng1 1Department of Pharmaceutics, School of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China; 2Department of Pharmacy, Shanghai Tenth Peopl...
Guardado en:
Autores principales: | Wu C, Zhang Y, Yang D, Zhang J, Ma J, Cheng D, Chen J, Deng L |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/97892511cf234233a019b48c2e3eee67 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
por: Xing J, et al.
Publicado: (2019) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi Y, et al.
Publicado: (2018) -
SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
por: Fang YP, et al.
Publicado: (2018) -
Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma
por: Alekseeva AA, et al.
Publicado: (2017) -
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
por: Chen M, et al.
Publicado: (2017)